Senores Pharmaceuticals Share Price
1439.40+9.00 (+0.63%)
+101.96% past 1 Year
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across
Corporate filings & documents
Announcements
We are submitting herewith the copy of Business Responsibility and Sustainability Report of the Company for the financial year 2025-26.
19 hours agoWe are submitting herewith the copy of Business Responsibility and Sustainability Report of the Company for the financial year 2025-26.
19 hours agoWe are submitting herewith the Annual Report of the Company for the financial year 2025-26.
19 hours agoWe are submitting herewith the Annual Report of the Company for the financial year 2025-26.
19 hours agoWe are submitting herewith the notice convening the 9th Annual general Meeting of the Company and Annual Report for the financial year 2025-26
19 hours agoWe are submitting herewith the notice convening the 9th Annual general Meeting of the Company and Annual Report for the financial year 2025-26
19 hours agoSenores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on September 02 2026
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on September 02 2026
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Independent Director
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Independent Director
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding appointment of Company Secretary and Compliance Officer of the Company
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding appointment of Company Secretary and Compliance Officer of the Company
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Subsidiary Company in Canada
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Subsidiary Company in Canada
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Wholly owned subsidiary in Mexico
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Wholly owned subsidiary in Mexico
1 week agoSenores Pharmaceuticals Limited has informed the Exchange about Outcome of Board Meeting held on August 26 2026
1 week agoSenores Pharmaceuticals Limited has informed the Exchange about Outcome of Board Meeting held on August 26 2026
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding giving corporate guarantee for credit facilities availed by Apnar Pharma Private Limited Subsidiary of the Company from ICICI Bank Limited
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding giving corporate guarantee for credit facilities availed by Apnar Pharma Private Limited Subsidiary of the Company from ICICI Bank Limited
1 week agoSenores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on August 25 2026
2 weeks agoSenores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on August 25 2026
2 weeks agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Dhananjay Barot
3 weeks agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Dhananjay Barot
3 weeks agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ashokkumar Vijaysinh Barot
3 weeks agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ashokkumar Vijaysinh Barot
3 weeks agoSenores Pharmaceuticals Limited has informed the Exchange regarding the Scrutinzer Report dated August 04 2026
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding the Scrutinzer Report dated August 04 2026
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Postal Ballot
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Postal Ballot
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Transcript of Earnings Conference Call held on Monday July 27 2026 for Q1FY27.
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Transcript of Earnings Conference Call held on Monday July 27 2026 for Q1FY27.
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Newspaper Publication Extracts of Unaudited Financial Results of the Company for quarter ended June 30 2026
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Newspaper Publication Extracts of Unaudited Financial Results of the Company for quarter ended June 30 2026
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Audio recording of Earnings Conference Call for the quarter ended June 30 2026
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Audio recording of Earnings Conference Call for the quarter ended June 30 2026
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible equity warrants for the quarter ended on June 30 2026.
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible equity warrants for the quarter ended on June 30 2026.
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended June 30 2026
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended June 30 2026
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for quarter ended June 30 2026
1 month agoSenores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for quarter ended June 30 2026
1 month agoSenores Pharmaceuticals Limited has informed the exchange regarding Investor Presentation for Q1FY27
1 month agoSenores Pharmaceuticals Limited has informed the exchange regarding Investor Presentation for Q1FY27
1 month agoSenores Pharmaceuticals Limited has informed the exchange regarding Media Release dated July 27 2026
1 month agoSenores Pharmaceuticals Limited has informed the exchange regarding Media Release dated July 27 2026
1 month agoSenores Pharmaceuticals Limited has informed the exchange regarding Appointment of Ms Anjali Shah as Assistant Vice President - Finance categorized as SMP of the Company w.e.f July 27 2026
1 month agoSenores Pharmaceuticals Limited has informed the exchange regarding Appointment of Ms Anjali Shah as Assistant Vice President - Finance categorized as SMP of the Company w.e.f July 27 2026
1 month agoAnnual reports
Concalls & investor presentations
Jul 2026
May 2026
Jan 2026
Nov 2025
ConcallPresentation
Jul 2025
ConcallPresentation
Jul 2025
ConcallPresentation
May 2025
ConcallPresentation
May 2025
ConcallPresentation
Jan 2025
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
1101 To 1103, 11th Floor, South Tower One 42 Opp. Jayantilal Park Ambali Bopal Road Ahmedabad Gujarat PIN: 380054 Tel No: 079-29999857 Fax No: NULL Email: [email protected] Internet: www.senorespharma.com
Registrars
C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai(Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra C 101, 247 Park LBS Marg Vikhroli (West) PIN: Tel No: +91 810 811 8484 Fax No: 91-022-49186060 Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Swapnil Jatinbhai Shah, Managing Director
Sanjay Shaileshbhai Majmudar, Chairman
Hemanshu Nitinchandra Pandya, Non Independent & Non Executive Director
Jitendra Babulal Sanghvi, Non Independent & Non Executive Director
Chetan Bipinchandra Shah, Whole Time Director & Chief Operating Officer
Deval Rajnikant Shah, Whole Time Director & Chief Financial Officer
Ashokkumar Vijaysinh Barot, Non Independent & Non Executive Director
Arpit Deepakkumar Shah, Non Independent & Non Executive Director
Naresh Bansilal Shah, Non Executive Independent Director
Manjula Devi Shroff, Non Executive Independent Director
Kalpit Rajesh Gandhi, Non Executive Independent Director
Udayan Dileep Choksi, Non Executive Independent Director
Details
BSE 544319
NSE SENORES
ISIN INE0RB801010